{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:45:47Z","timestamp":1790664347840,"version":"4.1.0"},"reference-count":55,"publisher":"Informa UK Limited","issue":"23","license":[{"start":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T00:00:00Z","timestamp":1687132800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Alkermes, Inc."}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.2217\/fon-2023-0246","type":"journal-article","created":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T04:39:01Z","timestamp":1687149541000},"page":"1577-1591","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":17,"title":["ARTISTRY-7: phase III trial of nemvaleukin alfa plus pembrolizumab vs chemotherapy for platinum-resistant ovarian cancer"],"prefix":"10.1080","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4584-8908","authenticated-orcid":false,"given":"Thomas J","family":"Herzog","sequence":"first","affiliation":[{"name":"University of Cincinnati Cancer Center,UC College of Medicine, \rCincinnati, \rOH 45267, \rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L","family":"Hays","sequence":"additional","affiliation":[{"name":"Wexner Medical Center & James Cancer Hospital,Ohio State University, \rColumbus, \rOH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce N","family":"Barlin","sequence":"additional","affiliation":[{"name":"Women\u2019s Cancer Care Associates, \rAlbany, \rNY 12208, \rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Buscema","sequence":"additional","affiliation":[{"name":"Arizona Oncology Associates, PC, \rTucson, \rAZ 85718, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelle G","family":"Cloven","sequence":"additional","affiliation":[{"name":"Texas Oncology \u2013 Fort Worth Cancer Center, \rFort Worth, \rTX 76104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3963-0088","authenticated-orcid":false,"given":"Lynn R","family":"Kong","sequence":"additional","affiliation":[{"name":"Ventura County Hematology Oncology Specialists, \rOxnard, \rCA 93930, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nidhi Kumar","family":"Tyagi","sequence":"additional","affiliation":[{"name":"Hamilton Health Sciences, \rHamilton, ON, \rL8N 3Z5, \rCanada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grainger S","family":"Lanneau","sequence":"additional","affiliation":[{"name":"ECU Health, \rGreenville, \rNC 27834, \rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beverly J","family":"Long","sequence":"additional","affiliation":[{"name":"Sarasota Memorial Healthcare System, \rSarasota, \rFL 34239, \rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L","family":"Marsh","sequence":"additional","affiliation":[{"name":"Virginia Cancer Specialists, \rGainesville, \rVA 20155, \rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelly M","family":"Seward","sequence":"additional","affiliation":[{"name":"Orlando Health, Inc., Orlando, FL 32806, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C","family":"Starks","sequence":"additional","affiliation":[{"name":"Avera Cancer Institute, \rSioux Falls, \rSD 57105, \rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Welch","sequence":"additional","affiliation":[{"name":"London Health Sciences Centre, \rLondon, ON, \rN6A 5A5, \rCanada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5803-0718","authenticated-orcid":false,"given":"Kathleen N","family":"Moore","sequence":"additional","affiliation":[{"name":"College of Medicine,University of Oklahoma, \rOklahoma City, OK 73117, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis A","family":"Konstantinopoulos","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, \rBoston, \rMA 02215, \rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Gilbert","sequence":"additional","affiliation":[{"name":"McGill University Health Centre,Women\u2019s Health Research Unit, \rMontr\u00e9al, QC, \rH3H 2R9, \rCanada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley J","family":"Monk","sequence":"additional","affiliation":[{"name":"HonorHealth Research Institute, University of Arizona College of Medicine,Creighton University School of Medicine, \rPhoenix, \rAZ 85012, \rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M","family":"O\u2019Malley","sequence":"additional","affiliation":[{"name":"Wexner Medical Center & James Cancer Hospital,Ohio State University, \rColumbus, \rOH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiwei","family":"Chen","sequence":"additional","affiliation":[{"name":"Alkermes, Inc., \rWaltham, \rMA 02451, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Dalal","sequence":"additional","affiliation":[{"name":"Alkermes, Inc., \rWaltham, \rMA 02451, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L","family":"Coleman","sequence":"additional","affiliation":[{"name":"US Oncology Research,The Woodlands, \rTX 77380, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jalid","family":"Sehouli","sequence":"additional","affiliation":[{"name":"Charit\u00e9 Universitaetsmedizin Berlin Charit\u00e9 Campus Virchow-Klinikum, \rBerlin, \r11017, \rGermany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,6,19]]},"reference":[{"key":"e_1_3_7_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_3_7_4_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21708"},{"key":"e_1_3_7_5_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S335936"},{"key":"e_1_3_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.07.004"},{"key":"e_1_3_7_7_1","unstructured":"National Comprehensive Cancer Network . Clinical practice guidelines in oncology. Ovarian cancer fallopian tube cancer and primary peritoneal cancer V.1.2023 (2022). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/ovarian_blocks.pdf"},{"key":"e_1_3_7_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.6735"},{"key":"e_1_3_7_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.4489"},{"key":"e_1_3_7_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-017-0960-z"},{"key":"e_1_3_7_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/jso.26416"},{"key":"e_1_3_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00216-3"},{"key":"e_1_3_7_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00334"},{"key":"e_1_3_7_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.5945"},{"key":"e_1_3_7_15_1","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2022.33.e45"},{"key":"e_1_3_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2020.07.028"},{"key":"e_1_3_7_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz135"},{"key":"e_1_3_7_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003831"},{"key":"e_1_3_7_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.3343"},{"key":"e_1_3_7_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02059"},{"key":"e_1_3_7_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.1048"},{"key":"e_1_3_7_22_1","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12040842"},{"key":"e_1_3_7_23_1","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12010124"},{"key":"e_1_3_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2021.09.011"},{"key":"e_1_3_7_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000673"},{"key":"e_1_3_7_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-016-1910-x"},{"key":"e_1_3_7_27_1","doi-asserted-by":"publisher","DOI":"10.2147\/ITT.S61590"},{"key":"e_1_3_7_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0522-3"},{"key":"e_1_3_7_29_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1002569107"},{"key":"e_1_3_7_30_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.163.3.1619"},{"key":"e_1_3_7_31_1","volume-title":"PROLEUKIN (aldesleukin) [prescribing information].","author":"Clinigen, Inc","year":"2019","unstructured":"Clinigen, Inc . PROLEUKIN (aldesleukin) [prescribing information].Clinigen, Inc., PA, USA (2019)."},{"key":"e_1_3_7_32_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.121.000612"},{"key":"e_1_3_7_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-06-2399"},{"key":"e_1_3_7_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2015.10.003"},{"key":"e_1_3_7_35_1","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/9056173"},{"key":"e_1_3_7_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2014.07.018"},{"key":"e_1_3_7_37_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2020-2202"},{"key":"e_1_3_7_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-009-0750-3"},{"key":"e_1_3_7_39_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.cji.0000155049.26787.45"},{"key":"e_1_3_7_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.01.001"},{"key":"e_1_3_7_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.01.035"},{"key":"e_1_3_7_42_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0594-0"},{"key":"e_1_3_7_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2016.01.001"},{"key":"e_1_3_7_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.07.012"},{"key":"e_1_3_7_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4321"},{"key":"e_1_3_7_46_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.2552"},{"key":"e_1_3_7_47_1","volume-title":"Immunotherapy Bridge 2021 and Melanoma Bridge 2021.","author":"Lewis K","year":"2021","unstructured":"Lewis K , BoniV, CalvoEet al. Nemvaleukin alfa (ALKS 4230) monotherapy in patients with advanced melanoma: ARTISTRY-1. Presented at: Immunotherapy Bridge 2021 and Melanoma Bridge 2021.1\u20134 December 2021 (Virtual)."},{"key":"e_1_3_7_48_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.4_suppl.659"},{"key":"e_1_3_7_49_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.2500"},{"key":"e_1_3_7_50_1","volume-title":"Society for Gynecologic Oncology Annual Meeting, March 18-21, 2022.","author":"Winer I","year":"2022","unstructured":"Winer I , VaishampayanUN, GilbertLet al. Clinical outcomes of ovarian cancer patients treated with the novel engineered cytokine nemvaleukin alfa in combination with the PD 1 inhibitor pembrolizumab: recent data from ARTISTRY 1. Presented at: Society for Gynecologic Oncology Annual Meeting, March 18-21, 2022.AZ, USA (2022)."},{"issue":"4","key":"e_1_3_7_51_1","first-page":"240","article-title":"Immunotherapy for ovarian cancer","volume":"20","author":"Porter R","year":"2022","unstructured":"Porter R , MatulonisUA. Immunotherapy for ovarian cancer. Clin. Adv. Hematol. Oncol.20(4), 240\u2013253 (2022).","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"e_1_3_7_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2021.02.031"},{"key":"e_1_3_7_53_1","unstructured":"U.S. Food and Drug Administration Clinical Guidance . Clinical trial endpoints for the approval of cancer drugs and biologics (2018). https:\/\/www.fda.gov\/media\/71195\/download"},{"key":"e_1_3_7_54_1","unstructured":"US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) . Guidance for industry: codevelopment of two or more new investigational drugs for use in combination (2013). https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/codevelopment-two-or-more-new-investigational-drugs-use-combination"},{"key":"e_1_3_7_55_1","volume-title":"AVASTIN (bevacizumab) injection, for intravenous use [prescribing information].","year":"2022","unstructured":"AVASTIN (bevacizumab) injection, for intravenous use [prescribing information]. Genentech, Inc, CA, USA (2022)."},{"key":"e_1_3_7_56_1","volume-title":"AVASTIN (bevacizumab) concentrate for solution for infusion [summary of product characteristics].","year":"2014","unstructured":"AVASTIN (bevacizumab) concentrate for solution for infusion [summary of product characteristics]. Roche Pharma AG, Grenzach-Wyhlen, Germany (2014)."},{"key":"e_1_3_7_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2023-0246","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T02:44:46Z","timestamp":1719110686000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2023-0246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,19]]},"references-count":55,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["10.2217\/fon-2023-0246"],"URL":"https:\/\/doi.org\/10.2217\/fon-2023-0246","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,19]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-03-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}